Menu Search
Equities

Rohto Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
RPHCF:PKL

Rohto Pharmaceutical Co Ltd

Actions
  • Price (USD)16.30
  • Today's Change0.00 / 0.00%
  • Shares traded60.00
  • 1 Year change--
  • Beta0.2923
Data delayed at least 15 minutes, as of Dec 02 2025 16:22 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Rohto Pharmaceutical Co Ltd is a Japan-based company primarily engaged in the manufacture and sale of eye care (eye drops, eyewash), skin care (external medications, lip balm, sunscreen, functional cosmetics), oral medication (gastrointestinal medicines, herbal medicines, supplements), and other products and services (in vitro diagnostic reagents) in the health and beauty care field. The Company operates through four regional segments. The Japan segment manufactures and sells eye care, skin care, oral medication, and other products (services). The Americas segment and the Europe segment mainly manufacture and sell skin care products (services). The Asia segment mainly manufactures and sells eye care and skin care products (services), as well as oral medication products (services).

  • Revenue in JPY (TTM)333.80bn
  • Net income in JPY35.74bn
  • Incorporated1949
  • Employees9.14k
  • Location
    Rohto Pharmaceutical Co Ltd1-8-1, Tatsumi-Nishi, Ikuno-kuOSAKA-SHI 544-8666JapanJPN
  • Phone+81 667581231
  • Websitehttps://www.rohto.co.jp
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4527:TYO since
announced		Transaction
value
Thann Oryza Co LtdAnnounced07 Jan 202607 Jan 2026Announced-2.60%--
Data delayed at least 15 minutes, as of Feb 06 2026 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.